These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19804366)

  • 1. Coagulation factor XIII variants with altered thrombin activation rates.
    Andersen MD; Kjalke M; Bang S; Lautrup-Larsen I; Becker P; Andersen AS; Olsen OH; Stennicke HR
    Biol Chem; 2009 Dec; 390(12):1279-83. PubMed ID: 19804366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit.
    Bagoly Z; Fazakas F; Komáromi I; Haramura G; Tóth E; Muszbek L
    Thromb Haemost; 2008 Apr; 99(4):668-74. PubMed ID: 18392324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study.
    Isetti G; Maurer MC
    Biochemistry; 2007 Mar; 46(9):2444-52. PubMed ID: 17286389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing thrombin's ability to accommodate a V34F substitution within the factor XIII activation peptide segment (28-41).
    Isetti G; Maurer MC
    J Pept Res; 2004 Mar; 63(3):241-52. PubMed ID: 15049836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin activity is unaltered by N-terminal truncation of factor XIII activation peptides.
    Isetti G; Maurer MC
    Biochemistry; 2004 Apr; 43(14):4150-9. PubMed ID: 15065858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of factor XIII activation peptide (28-41) V34L mutant bound to thrombin.
    Nair DG; Sunilkumar PN; Sadasivan C
    J Biomol Struct Dyn; 2008 Dec; 26(3):387-94. PubMed ID: 18808204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation.
    Trumbo TA; Maurer MC
    Biochemistry; 2002 Feb; 41(8):2859-68. PubMed ID: 11851434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.
    Ariëns RA; Philippou H; Nagaswami C; Weisel JW; Lane DA; Grant PJ
    Blood; 2000 Aug; 96(3):988-95. PubMed ID: 10910914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FXIII polymorphisms, fibrin clot structure and thrombotic risk.
    Kobbervig C; Williams E
    Biophys Chem; 2004 Dec; 112(2-3):223-8. PubMed ID: 15572253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of factor XIII solvent accessibility as a function of activation state using chemical modification methods.
    Turner BT; Sabo TM; Wilding D; Maurer MC
    Biochemistry; 2004 Aug; 43(30):9755-65. PubMed ID: 15274630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.
    Jadhav MA; Isetti G; Trumbo TA; Maurer MC
    Biochemistry; 2010 Apr; 49(13):2918-24. PubMed ID: 20218626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form.
    Schroeder V; Vuissoz JM; Caflisch A; Kohler HP
    Thromb Haemost; 2007 Jun; 97(6):890-8. PubMed ID: 17549290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
    Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
    Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.
    Jadhav MA; Lucas RC; Goldsberry WN; Maurer MC
    Biochim Biophys Acta; 2011 Dec; 1814(12):1955-63. PubMed ID: 21798378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A.
    Lee IH; Chung SI; Lee SY
    Exp Mol Med; 2002 Nov; 34(5):385-90. PubMed ID: 12526104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
    Duval C; Ali M; Chaudhry WW; Ridger VC; Ariëns RA; Philippou H
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):308-16. PubMed ID: 26743168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing interactions between the coagulants thrombin, Factor XIII, and fibrin(ogen).
    Maurer MC; Trumbo TA; Isetti G; Turner BT
    Arch Biochem Biophys; 2006 Jan; 445(1):36-45. PubMed ID: 16364233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma.
    Shemirani AH; Haramura G; Bagoly Z; Muszbek L
    Biochim Biophys Acta; 2006 Aug; 1764(8):1420-3. PubMed ID: 16920044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
    Siebenlist KR; Meh DA; Mosesson MW
    Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function.
    Muszbek L; Adány R; Mikkola H
    Crit Rev Clin Lab Sci; 1996; 33(5):357-421. PubMed ID: 8922891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.